CANbridge Pharmaceuticals

Categories

Life SciencesPharmaceuticals

About Us

Established in 2012, CANbridge is a leading China-based, global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies.

We are led by a seasoned management team with significant industry experience in rare diseases, spanning R&D, clinical development, regulatory affairs, business development and commercialization, supported by a pool of talent of 151 employees where 22 had a Ph.D. and/or M.D. degree and more than 80% of our employees had experience working at multinational biopharmaceutical companies as of June 21, 2021. Our management team collectively has a track record of successfully commercializing rare disease therapies across the key markets including China, the United States, Europe, Latin America, and Southeast Asia. Leveraging our managementā€™s expertise, we play an active role in advancing the rare disease industry and shaping the rare disease ecosystem in China. For example, our founder Dr. Xue is currently serving as the Deputy Director General of Chinaā€™s Alliance for Rare Disease (CHARD).

As of June 21,2021, we had developed a comprehensive and differentiated pipeline of 13 drug assets with significant market potential targeting some of the most prevalent rare diseases as well as rare oncology indications, including three marketed products, three drug candidates at clinical stage, two at IND-enabling stage, two at preclinical stage and another three gene therapy programs at lead identification stage.

Rep/Contact Info

Linda Farr
Pavan Ghatty
Scroll to Top